Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03877718
Other study ID # CL02-204
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date February 1, 2019
Est. completion date August 27, 2019

Study information

Verified date March 2019
Source Charleston Laboratories, Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain.


Description:

A Multicenter, Randomized, Double-Blind, Comparator-Controlled, Placebo-Controlled Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain, With or Without Aura, and the Prevention of Migraineā€‘Associated Nausea and Vomiting (MANV)


Recruitment information / eligibility

Status Completed
Enrollment 475
Est. completion date August 27, 2019
Est. primary completion date August 27, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Able to understand and willing to give written informed consent and authorize the Health Insurance Portability and Accountability Act (HIPAA) prior to entering the study.

2. Men and women with episodic migraine who meet the criteria of the International Headache Society's Headache Classification Committee for migraine with or without aura.

3. Between the ages of 18 and 75 years of age, inclusive.

4. A history of episodic migraine for at least 1 year.

5. Maximal frequency of 8 migraine attacks per month; minimum frequency of 2 migraine attacks per month; at least 48 hours of headache-free time between migraine attacks.

6. Maximum total headache days of 14 per month.

7. History of migraine headache with nausea = 50% of the time.

8. Able and willing to complete an electronic diary (eDiary) to record the details of a migraine attack treated with investigational treatment.

9. Able to swallow a capsule whole.

10. Report headache on the Headache Pain Scale at Baseline before treatment.

11. Report the presence of nausea on the Nausea Scale at Baseline before treatment.

12. Women of childbearing potential (WOCBP) must practice an acceptable method of birth control (acceptable methods of birth control in this study include: surgical sterilization, intrauterine device, oral contraceptive, contraceptive patch, long-acting injectable contraceptive, partner's vasectomy, or a double-barrier method [condom or diaphragm with spermicide]). Use of intrauterine devices and hormonal contraceptives must begin at least 8 weeks prior to Screening.

13. Willing and able to comply with the protocol requirements for the duration of the study.

Exclusion Criteria:

1. A clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation. Such conditions may include cardiac, respiratory, hepatic, renal or metabolic diseases, peripheral vascular disease, any systemic disease, acute infection, or neurological disease (including Parkinson's Disease or other condition associated with a movement disorder), current malignancy or recent history (within 5 years) of malignancy (other than squamous cell or basal cell carcinoma) or any medical condition that, in the opinion of the Investigator, makes the subject unsuitable for participation in the study.

2. A positive saliva screen for alcohol or a positive urine drug screen for cocaine, narcotics, benzodiazepines, opioids, tetrahydrocannabinol (THC), barbiturates, amphetamines, or any prescription drugs unless such a positive result can be explained by stated concomitant medications.

3. Regularly smoke cigarettes or use opiate analgesic drugs, benzodiazepines, ergot containing drugs, alcohol, THC, or other drugs of abuse that, at the discretion of the Investigator, may interfere with the evaluation of the endpoints in the trial.

4. Unstable use of prophylactic migraine medication (eg, change of dose or type of medication) during the 30 days prior to Screening Visit.

5. Subjects using monoamine oxidase-A (MAO-A) inhibitors and who cannot be washed out.

6. Subjects using selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, THC, or systemic corticosteroids over the past month prior to the Screening Visit.

7. Daily use of antipsychotics at least 15 days prior to randomization.

8. Medication overuse:

1. Opioids for headache = 10 days during the 90 days prior to Screening Visit;

2. Combination medications that contain an opioid and/or barbiturate (eg, FiorinalĀ®) = 10 days during the 90 days prior to Screening Visit.

3. Nonsteroidal anti-inflammatory drugs (NSAIDs) or other simple medications ? 14 days a month during the 90 days prior to Screening Visit.

4. Triptans or ergots = 10 days a month during the 90 days prior to Screening Visit.

9. Use of mini prophylaxis for menstrual migraine.

10. History of allergic reaction or drug sensitivity to any triptans.

11. History of allergic reaction or drug sensitivity to promethazine.

12. History of allergic reaction or drug sensitivity to acetaminophen.

13. History of extrapyramidal reaction (eg, akathisia or dystonia) to neuroleptic treatments.

14. Subjects who are pregnant (positive urine hCG: Human chorionic gonadotropin test at Screening Visit) or breastfeeding.

15. Use of experimental or investigational treatments and/or participation in drug clinical studies within the 6 months before the Screening Visit.

16. Subjects who are employees of the Sponsor.

17. Relatives of, or staff directly reporting to, the Investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Arm 1: CL-H1T
One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 18.75 mg)
Arm 2: CL-H1T
One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 37.5 mg)
Arm 3: Sumatriptan Succinate 100 mg capsule
One capsule of sumatriptan succinate 100 mg
Arm 4: Promethazine HCl 18.75 mg
One capsule of promethazine HCl 18.75 mg
Arm 5: Promethazine HCl 37.5 mg
One capsule of promethazine HCl 37.5 mg
Other:
Placebo
One capsule of placebo

Locations

Country Name City State
United States Mountain View Cl inical Research, Inc. Greer South Carolina
United States Suncoast Clinical Research, Inc. New Port Richey Florida
United States Harmony Clinical Research, Inc. North Miami Beach Florida

Sponsors (1)

Lead Sponsor Collaborator
Charleston Laboratories, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of subjects who are pain-free 2 hours after taking investigational treatment 2 hours
Primary Percentage of subjects who are nausea-free 2 hours after taking investigational treatment 2 hours
Secondary Percentage of subjects with no vomiting 2 hours after taking the investigational treatment 2 hours
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05559255 - Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI N/A
Completed NCT04748367 - Leveraging on Immersive Virtual Reality to Reduce Pain and Anxiety in Children During Immunization in Primary Care N/A
Terminated NCT04356352 - Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain Phase 2/Phase 3
Completed NCT05057988 - Virtual Empowered Relief for Chronic Pain N/A
Completed NCT04466111 - Observational, Post Market Study in Treating Chronic Upper Extremity Limb Pain
Recruiting NCT06206252 - Can Medical Cannabis Affect Opioid Use?
Completed NCT05868122 - A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy Phase 3
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Completed NCT03273114 - Cognitive Functional Therapy (CFT) Compared With Core Training Exercise and Manual Therapy (CORE-MT) in Patients With Chronic Low Back Pain N/A
Enrolling by invitation NCT06087432 - Is PNF Application Effective on Temporomandibular Dysfunction N/A
Completed NCT05508594 - Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001 Phase 2/Phase 3
Recruiting NCT03646955 - Partial Breast Versus no Irradiation for Women With Early Breast Cancer N/A
Active, not recruiting NCT03472300 - Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals
Completed NCT03678168 - A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries N/A
Completed NCT03931772 - Online Automated Self-Hypnosis Program N/A
Completed NCT03286543 - Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System N/A
Completed NCT02913027 - Can We Improve the Comfort of Pelvic Exams? N/A
Terminated NCT02181387 - Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor? Phase 4
Recruiting NCT06032559 - Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment Phase 3
Active, not recruiting NCT03613155 - Assessment of Anxiety in Patients Treated by SMUR Toulouse and Receiving MEOPA as Part of Their Care